Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

Novartis Pharmaceuticals · 2024
ClinicalTrials.gov · Datasets · License: Public Domain · 2024
Open Source ↗
oligometastatic prostate cancer (ompc), lutetium (177lu) vipivotide tetraxetan, metastasis free survival (mfs), gallium (68ga) gozetotide, piflufolastat (18f), prostate-specific membrane antigen (psma), delay castration, stereotactic body radiation therapy (sbrt), metastasis-directed therapy, androgen deprivation therapy (adt)-free survival., interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 982200
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.